London and South East Sarcoma Network

<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"> <html> <head> <meta http-equiv="Content-type" content="text/html;charset=UTF-8"> <title>London and South East Sarcoma Network</title> <meta name="Description" content="The diagnosis and treatment of cancer requires a team of experts with a variety of skills and training. To promote best care, patients with sarcomas have their management discussed at a multidisciplinary team (MDT) meeting."> <link rel="stylesheet" type="text/css" href="global.css"> <link rel="icon" type="image/png" href="images/favicon.png"> <script type="text/javascript"> var _gaq = _gaq || []; _gaq.push(['_setAccount', 'UA-5238196-4']); _gaq.push(['_trackPageview']); (function() { var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true; ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js'; var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s); })(); </script> </head> <body id="page_trials"> <div id="wrapper">  <div id="header"> <div id="logo"> <a href="index.html" title="home"><img src="images/nhs-logo.gif" alt="NHS logo"></a> London and South East<br>Sarcoma Network </div> </div>  <div id="nav-wrapper"> <div id="nav"> <ul> <li id="nav_home"><a href="index.html">Home</a></li> <li id="nav_sarcoma"><a href="sarcoma.html">Pathways</a></li> <li id="nav_referrers"><a href="referrers.html">For referrers</a></li> <li id="nav_guidelines"><a href="guidelines.html">Guidelines</a></li> <li id="nav_trials"><a href="trials.html">Trials</a></li> <li id="nav_group"><a href="group.html">SAG</a></li> <li id="nav_links"><a href="links.html">Links</a></li> <li id="nav_patient"><a href="patient.html">For patients</a></li> </ul> </div> </div>   <div id="content-wrapper"> <h1>Clinical trials</h1> <p>The following list shows the clinical trials currently open at the two sarcoma centres in London and the South East: University College London (UCLH) and The Royal Marsden (RMH). For further information please contact the research nurses at each site:</p> <ul> <li>UCLH: Tara Searle (<a href="mailto:tara.searle@nhs.net">tara.searle@nhs.net</a>)</li> <li>RMH: Stephanie Elston (<a href="mailto:Stephanie.Elston@rmh.nhs.uk">Stephanie.Elston@rmh.nhs.uk</a>)</li> </ul> <p>Last updated January 2025</p> <table summary="Sarcoma clinical trials" class="table" cellpadding="0" cellspacing="0"> <thead> <tr> <th scope="col">Name</th> <th scope="col">Description</th> <th scope="col">Type</th> <th scope="col">Centre</th> <th scope="col">Age</th> </tr> </thead> <tbody> <tr> <td>ADCT-601</td> <td>A Phase Ib, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Mipasetamab Uzoptirine (ADCT-601) Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with Selected Advanced Solid Tumors</td> <td>Phase Ib</td> <td>RMH</td> <td></td> </tr> <tr> <td>AGENUS C-800-01</td> <td>A Phase I Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination with AGEN2034 (balstilimab), an Anti-PD-1 Monoclonal Antibody, in Subjects with Advanced Cancer</td> <td>Phase I </td> <td>RMH</td> <td></td> </tr> <tr> <td>BRIGHTLINE 4</td> <td>A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of brigimadlin (BI 907828) treatment in patients with treatment-naïve or pretreated advanced dedifferentiated liposarcoma</td> <td>Phase III</td> <td>RMH</td> <td></td> </tr> <tr> <td>EHE Biobank</td> <td>UK Biobank for epithelioid haemangioendothelioma</td> <td></td> <td>RMH</td> <td></td> </tr> <tr> <td>EHE Study Milan</td> <td>Evaluation of cytokines and hormonal profile as biomarker in epithelioid haemangioendothelioma </td> <td></td> <td>RMH</td> <td></td> </tr> <tr> <td>FaR RMS</td> <td>An overarching study for children and adults with frontline and relapsed rhabdomyosarcoma</td> <td></td> <td>RMH, <br>UCLH</td> <td>>12 months, ≤40 years </td> </tr> <tr> <td>GIST Biobank </td> <td>Biobank for GIST </td> <td></td> <td>RMH</td> <td></td> </tr> <tr> <td>ICONIC</td> <td>Improving outcomes through collaboration in osteosarcoma</td> <td></td> <td>UCLH</td> <td></td> </tr> <tr> <td>IDRx</td> <td>First in Human study of IDRx-42 in patients with metastatic/unresectable GIST following progression on imatinib only or treatment naïve</td> <td>Phase lb</td> <td>RMH</td> <td></td> </tr> <tr> <td>INSIGHT</td> <td>Ripretinib vs Sunitinib. GIST with KIT Exon 11 and Co occurring KIT Exons 17 and/or 18 Mutations</td> <td>Phase III</td> <td>RMH</td> <td></td> </tr> <tr> <td>Inter-Ewings</td> <td>International clinical research programme to improve outcomes in newly diagnosed Ewing sarcoma – Trial 1 (INTER-EWING-1)</td> <td></td> <td>UCLH</td> <td>>2 years</td> </tr> <tr> <td>INBRX-109 (ChonDRAgon)</td> <td>A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma</td> <td>Phase II</td> <td>RMH,<br>UCLH</td> <td>>18 and <85 years</td> </tr> <tr> <td>KINDRED</td> <td>The International Sarcoma Kindred Study: a global multi‐site prospective cancer genetics study.</td> <td>Translational</td> <td>RMH<br>UCLH</td> <td>≥15 years</td> </tr> <tr> <td>NEWBAY</td> <td>A Multicenter Phase 1, Open-Label Study of NB003 to Assess Safety, Tolerability, Pharmacokinetics and Efficacy in Patients with Advanced Malignancies</td> <td>Phase I</td> <td>RMH</td> <td></td> </tr> <tr> <td>OligoRARE (EORTC 1945) </td> <td>Stereotactic body radiotherapy in addition to standard of care treatment in patients with rare oligometastatic cancers (OligoRARE): a randomized, phase 3, open-label trial </td> <td>Phase III</td> <td>RMH</td> <td></td> </tr> <tr> <td>Pharma Mar</td> <td>Randomized, Controlled, Open-label, Phase IIb/III Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First-line Treatment in Patients with Metastatic Leiomyosarcoma</td> <td>Phase IIb/III</td> <td>RMH,<br>UCLH</td> <td>>18</td> </tr> <tr> <td>PREDICT B</td> <td>Predicting radiotherapy response, toxicities and quality of life related functional outcome in soft tissue sarcoma of the extremities: a prospective observational cohort study</td> <td></td> <td>RMH,<br>UCLH</td> <td>≥16 years</td> </tr> <tr> <td>Radiomics in Liposarcoma </td> <td>Radiomics In Liposarcoma </td> <td></td> <td>RMH</td> <td></td> </tr> <tr> <td>rEECur</td> <td>International randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory ewing sarcoma.</td> <td>Phase II/III</td> <td>RMH<br>UCLH</td> <td>>4 years and < 50 years </td> </tr> <tr> <td>RT Immune</td> <td>A European, Multicentre, Randomized, Open-label, Phase II Trial, aiming to assess the clinical and biological activity of an anti-PD-L1 (atezolizumab) in operable localised soft tissue sarcomas patients to be treated with radiotherapy.</td> <td>Phase II</td> <td>RMH</td> <td></td> </tr> <tr> <td>STRASS 2</td> <td>A randomized phase III study of neoadjuvant chemotherapy followed by surgery versus surgery alone.</td> <td>Phase III</td> <td>RMH</td> <td></td> </tr> </tbody> </table> </div> </div> <div id="footer-wrapper"> <div id="footer"> <p>© 2012 London and South East Sarcoma Network, All rights reserved<br> <a href="terms.html">Terms and conditions</a> | <a href="privacy.html">Privacy and cookies policy</a></p> </div> </div> </div> </body> </html>

CINXE.COM

London and South East Sarcoma Network